

## Press Release

14 April 2025 12:00:00 CEST

# EARLY NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ)

The shareholders of 2cureX AB (publ) are hereby informed of the upcoming Annual General Meeting (AGM), which will take place on Thursday, June 26, 2025, at 15:00 CEST at the offices of Forvis Mazars, located at Nordenskiöldsgatan 11A, 211 19 Malmö, Sweden.

### Agenda Highlight: Proposed Dividend Distribution

At the AGM, the Board of Directors will propose initiating dividend payments from the proceeds previously received through the sale of 2cureX A/S. As approved at the EGM held on July 12, 2024, 2cureX A/S was sold to a consortium of international investors for SEK 5.6 million.

Following this transaction, the Board resolved that the full amount would be distributed proportionally to 2cureX AB shareholders. After consultations with the Company's newly appointed auditor, the Board has concluded that the dividend will need to be distributed in a number of tranches for accounting and compliance purposes.

A formal and detailed Notice of the AGM, including the exact amount of the first dividend tranche, will be published in advance of the meeting, in accordance with legal requirements.

Ole Thastrup, Chairman of the Board of Directors, commented:

*"It is a pleasure to confirm that 2cureX AB will now begin distributing the proceeds from the sale of 2cureX A/S as dividend to our shareholders. While we had anticipated initiating payments earlier, the delay was due to an intense operational period within the company. Dividend payments from growth-stage companies are rare, and this move reflects our deep appreciation for the continued trust and support of our shareholders."*

For further details and updates regarding the AGM, please refer to the official notice to be published in due course.

For more information about 2cureX:

---

Ole Thastrup, Chairman of the Board  
E-mail: [ot@2curex.com](mailto:ot@2curex.com)  
Telephone: +45 2211 5399

Kenneth Graabek Johansen, Chief Financial Officer  
E-mail: [kgj@2curex.com](mailto:kgj@2curex.com)  
Telephone: +45 23 49 02 27

## About 2cureX

---

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit [www.2cureX.se](http://www.2cureX.se)

Certified Adviser: Redeye AB

## Attachments

---

[EARLY NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB \(publ\)](#)